Professor Sir Martin Landray
Professor of Medicine and Epidemiology
- Deputy Director, Big Data Institute
- MRC Investigator
- Lead, Big Data & Computing Innovation, MRC Population Health Research Unit
- Lead, Clinical Informatics & Big Data, NIHR Oxford Biomedical Research Centre
- Honorary Consultant Physician, Oxford University Hospitals NHS Foundation Trust
Martin Landray is Professor of Medicine & Epidemiology and Deputy Director of the Big Data Institute at the Nuffield Department of Population Health, University of Oxford.
Prof Landray’s work seeks to further understanding of the determinants of common diseases chiefly through the design, conduct and analysis of efficient, large-scale clinical trials. He has led a series of major clinical trials, chiefly of treatments for cardiovascular and kidney disease. These trials have enrolled over 100,000 individuals and produced results that have changed regulatory drug approvals, influenced clinical guidelines and changed prescribing practice to the benefit of patients. Since March 2020, he has co-led the RECOVERY trial, the world’s largest trial of potential treatments for COVID-19, publishing definitive results for 10 treatments which have changed clinical practice worldwide.
Much of his work seeks to facilitate the conduct of randomised controlled trials to address major public health issues: He leads the Good Clinical Trials Collaborative in the development, promotion and adoption of guidelines for randomised controlled trials, supported by the Wellcome Trust and Bill & Melinda Gates Foundation. He leads Protas, a not-for-profit organisation focused on smarter randomised trials for better public health. In 2021, he was appointed to the Pandemic Preparedness Partnership leading to the publication of the G7 100 Days Mission to Respond to Future Pandemic Threats which recommended significant regulatory improvements to facilitate the rapid generation of relevant and robust results from innovative randomised controlled trials.
Prof Landray completed medical training at University of Birmingham (UK) and specialist training in Clinical Pharmacology & Therapeutics and General Internal Medicine at University of Birmingham. He continues to practise clinical medicine as an Honorary Consultant Physician in the Department of Cardiology at Oxford University Hospitals NHS Foundation Trust. In 2021 he was elected Fellow of the Academy of Medical Sciences and was knighted for services to public health and science.
Allocated but not treated: the silent 16% - Authors' reply.
Horby P. et al, (2022), Lancet (London, England), 399, 1775 - 1776
Feasibility of Randomizing Danish Citizens Aged 65-79 Years to High-Dose Quadrivalent Influenza Vaccine vs. Standard-Dose Quadrivalent Influenza Vaccine in a Pragmatic Registry-Based Setting: Rationale and Design of the DANFLU-1 Trial
LANDRAY M., (2022), Pilot and Feasibility Studies
Casirivimab+imdevimab in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial
LANDRAY M. et al, (2021), The Lancet
Colchicine in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial
Horby PW. et al, (2021), Lancet Respiratory Medicine, 9, 1419 - 1426
Aspirin in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial
LANDRAY M. et al, (2021), The Lancet
IN the News
Lectures, webcasts and interviews
RECOVERY - reflections and future directions
British Pharmacological Society, September 2021
Big Trials, Big Data, Big Potential: population health research in the 21st century
Inaugural Lecture, University of Oxford, November 2015